192 related articles for article (PubMed ID: 15014014)
1. Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy.
Wang H; Li M; Rinehart JJ; Zhang R
Clin Cancer Res; 2004 Mar; 10(5):1633-44. PubMed ID: 15014014
[TBL] [Abstract][Full Text] [Related]
2. Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine.
Wang H; Li M; Rinehart JJ; Zhang R
Cancer Chemother Pharmacol; 2004 Jun; 53(6):459-67. PubMed ID: 14752578
[TBL] [Abstract][Full Text] [Related]
3. Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics.
Wang H; Wang Y; Rayburn ER; Hill DL; Rinehart JJ; Zhang R
Int J Oncol; 2007 Apr; 30(4):947-53. PubMed ID: 17332934
[TBL] [Abstract][Full Text] [Related]
4. Dexamethasone enhances the antitumor efficacy of Gemcitabine by glucocorticoid receptor signaling.
Gong JH; Zheng YB; Zhang MR; Wang YX; Yang SQ; Wang RH; Miao QF; Liu XJ; Zhen YS
Cancer Biol Ther; 2020 Apr; 21(4):332-343. PubMed ID: 31906826
[TBL] [Abstract][Full Text] [Related]
5. Preclinical PK/PD model for the combinatorial use of dexamethasone and sulpiride in the treatment of breast cancer.
Yao QY; Li J; Chen R; Yao Y; Xue JS; Chen WJ; Lu W; Zhou TY
Acta Pharmacol Sin; 2019 Dec; 40(12):1596-1602. PubMed ID: 31165782
[TBL] [Abstract][Full Text] [Related]
6. Phase II randomized trial of carboplatin and gemcitabine with or without dexamethasone pre-treatment in patients with Stage IV non-small cell lung cancer.
Rinehart J; Arnold S; Kloecker G; Lim A; Zaydan MA; Baeker T; Maheshwari JG; Carloss H; Slone S; Shelton B; Croley J; Kvale E; Brooks M; Leggas M
Cancer Chemother Pharmacol; 2013 May; 71(5):1375-83. PubMed ID: 23475103
[TBL] [Abstract][Full Text] [Related]
7. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models.
Merriman RL; Hertel LW; Schultz RM; Houghton PJ; Houghton JA; Rutherford PG; Tanzer LR; Boder GB; Grindey GB
Invest New Drugs; 1996; 14(3):243-7. PubMed ID: 8958178
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.
Higgins B; Kolinsky K; Smith M; Beck G; Rashed M; Adames V; Linn M; Wheeldon E; Gand L; Birnboeck H; Hoffmann G
Anticancer Drugs; 2004 Jun; 15(5):503-12. PubMed ID: 15166626
[TBL] [Abstract][Full Text] [Related]
10. Semi-Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for the Combination Use of Dexamethasone and Gemcitabine in Breast Cancer.
Yuan Y; Zhou X; Ren Y; Zhou S; Wang L; Ji S; Hua M; Li L; Lu W; Zhou T
J Pharm Sci; 2015 Dec; 104(12):4399-4408. PubMed ID: 26344053
[TBL] [Abstract][Full Text] [Related]
11. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Pegram MD; Konecny GE; O'Callaghan C; Beryt M; Pietras R; Slamon DJ
J Natl Cancer Inst; 2004 May; 96(10):739-49. PubMed ID: 15150302
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity.
Wang H; Hang J; Shi Z; Li M; Yu D; Kandimalla ER; Agrawal S; Zhang R
Int J Oncol; 2002 Jul; 21(1):73-80. PubMed ID: 12063552
[TBL] [Abstract][Full Text] [Related]
13. Dose escalating study of biweekly gemcitabine and carboplatin in patients with advanced cancer.
Dudek AZ; Larson T; Keshtgarpour M; Kumar P
Am J Clin Oncol; 2007 Oct; 30(5):481-6. PubMed ID: 17921707
[TBL] [Abstract][Full Text] [Related]
14. The development of gemcitabine and carboplatin in the treatment of non-small-cell lung cancer.
Cullen M
Lung Cancer; 2005 Oct; 50 Suppl 1():S5-7. PubMed ID: 16291432
[TBL] [Abstract][Full Text] [Related]
15. Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.
Konecny G; Untch M; Slamon D; Beryt M; Kahlert S; Felber M; Langer E; Lude S; Hepp H; Pegram M
Breast Cancer Res Treat; 2001 Jun; 67(3):223-33. PubMed ID: 11561768
[TBL] [Abstract][Full Text] [Related]
16. A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients.
Tham LS; Wang L; Soo RA; Lee SC; Lee HS; Yong WP; Goh BC; Holford NH
Clin Cancer Res; 2008 Jul; 14(13):4213-8. PubMed ID: 18594002
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker.
Joshi A; Guo J; Holleran JL; Kiesel B; Taylor S; Christner S; Parise RA; Miller BM; Ivy SP; Chu E; Venkataramanan R; Beumer JH
Cancer Chemother Pharmacol; 2020 Oct; 86(4):535-545. PubMed ID: 32948918
[TBL] [Abstract][Full Text] [Related]
18. Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.
Diéras V; Bonnefoi H; Alba E; Awada A; Coudert B; Pivot X; Gligorov J; Jager A; Zambelli S; Lindeman GJ; Charpentier E; Emmons GT; Garcia-Ribas I; Paridaens R; Verweij J
Breast Cancer Res Treat; 2019 Sep; 177(2):383-393. PubMed ID: 31172407
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine and carboplatin in combination: phase I and phase II studies.
Langer CJ; Calvert P; Ozols RF
Semin Oncol; 1998 Aug; 25(4 Suppl 9):51-4. PubMed ID: 9728585
[TBL] [Abstract][Full Text] [Related]
20. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials.
Shalinsky DR; Brekken J; Zou H; McDermott CD; Forsyth P; Edwards D; Margosiak S; Bender S; Truitt G; Wood A; Varki NM; Appelt K
Ann N Y Acad Sci; 1999 Jun; 878():236-70. PubMed ID: 10415735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
